Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Chen-Hao Kuo, Bo-Son Kou & Shau-Wei Tsai. (2020) CALB-catalyzed kinetic resolution of (RS)-3-benzoylthio-2-methylpropyl azolides: kinetic and thermodynamic analysis. Biocatalysis and Biotransformation 38:5, pages 376-384.
Read now
Read now
Hong Xie, Gaoqing Luo, Yong Zheng, Feng Peng & Liangdi Xie. (2017) A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. Clinical and Experimental Hypertension 39:5, pages 421-426.
Read now
Read now
Stefano Omboni & Claudio Borghi. (2011) Zofenopril and incidence of cough: a review of published and unpublished data. Therapeutics and Clinical Risk Management 7, pages 459-471.
Read now
Read now
G. Carlucci, L. Di Federico & P. Iuliani. (2010) Simultaneous Determination of Zofenopril and Hydrochlorothiazide in Tablets Using Derivative UV Spectrophotometry. Analytical Letters 43:16, pages 2609-2617.
Read now
Read now
Krzysztof Narkiewicz. (2007) Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Pressure 16:sup2, pages 7-12.
Read now
Read now
Thomas Hedner, Krzysztof Narkiewicz & Sverre E. Kjeldsen. (2007) The evolution of ACE inhibition – A turning point in cardiovascular medicine. Blood Pressure 16:sup2, pages 5-6.
Read now
Read now
Articles from other publishers (10)
Charles S Wiysonge, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi & Lionel H Opie. (2017) Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
A A Kirichenko. (2014) Comparative evaluation of zofenopril. Are the characteristics of angiotensin I converting enzyme inhibitors important for the practice?. Systemic Hypertension 11:3, pages 39-43.
Crossref
Crossref
Enrico Agabiti-Rosei, Athanasios Manolis, Dario Zava & Stefano Omboni. (2014) Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients. Advances in Therapy 31:2, pages 217-233.
Crossref
Crossref
Thippani Ramesh, Pothuraju Nageswara Rao & Ramisetti Nageswara Rao. (2014) LC–MS/MS characterization of forced degradation products of zofenopril. Journal of Pharmaceutical and Biomedical Analysis 88, pages 609-616.
Crossref
Crossref
Charles Shey Wiysonge, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi, Anthony Mbewu & Lionel H Opie. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Charles Shey Wiysonge, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi, Anthony Mbewu & Lionel H Opie. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
C. Napoli. (2011) Safety and efficacy of the sulfydryl ACE-inhibitor zofenopril in the management of cardiovascular disease. Cardiovascular Therapy and Prevention 10:6, pages 99-104.
Crossref
Crossref
Giuseppe Carlucci, Lucia Di Federico & Piera Iuliani. (2010) HPLC-DAD method for the simultaneous determination of zofenopril and hydrochlorothiazide in oral pharmaceutical formulations. Journal of Separation Science 33:12, pages 1717-1722.
Crossref
Crossref
Stefano Omboni, Ettore Malacco & Gianfranco Parati. (2009) Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions. Cardiovascular Therapeutics 27:4, pages 275-288.
Crossref
Crossref
Claudio Napoli. (2009) Safety and Efficacy of the bi-Sulfydryl ACE-Inhibitor Zofenopril in the Management of Cardiovascular Disease. Clinical Medicine. Therapeutics 1, pages CMT.S2796.
Crossref
Crossref